NCCN Guidelines Insights: Melanoma, Version 3.2016

Daniel G Coit; John A Thompson; Alain Algazi; Robert Andtbacka; Christopher K Bichakjian; William E Carson 3rd; Gregory A Daniels; Dominick DiMaio; Ryan C Fields; Martin D Fleming; Brian Gastman; Rene Gonzalez; Valerie Guild; Douglas Johnson; Richard W Joseph; Julie R Lange; Mary C Martini; Miguel A Materin; Anthony J Olszanski; Patrick Ott; Aparna Priyanath Gupta; Merrick I Ross; April K Salama; Joseph Skitzki; Susan M Swetter; Kenneth K Tanabe; Javier F Torres-Roca; Vijay Trisal; Marshall M Urist; Nicole McMillian; Anita Engh

doi:10.6004/jnccn.2016.0101

NCCN Guidelines Insights: Melanoma, Version 3.2016

J Natl Compr Canc Netw. 2016 Aug;14(8):945-58. doi: 10.6004/jnccn.2016.0101.

Authors

Daniel G Coit¹, John A Thompson¹, Alain Algazi¹, Robert Andtbacka¹, Christopher K Bichakjian¹, William E Carson 3rd¹, Gregory A Daniels¹, Dominick DiMaio¹, Ryan C Fields¹, Martin D Fleming¹, Brian Gastman¹, Rene Gonzalez¹, Valerie Guild¹, Douglas Johnson¹, Richard W Joseph¹, Julie R Lange¹, Mary C Martini¹, Miguel A Materin¹, Anthony J Olszanski¹, Patrick Ott¹, Aparna Priyanath Gupta¹, Merrick I Ross¹, April K Salama¹, Joseph Skitzki¹, Susan M Swetter¹, Kenneth K Tanabe¹, Javier F Torres-Roca¹, Vijay Trisal¹, Marshall M Urist¹, Nicole McMillian¹, Anita Engh¹

Affiliation

¹ From Memorial Sloan Kettering Cancer Center; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; UCSF Helen Diller Family Comprehensive Cancer Center; Huntsman Cancer Institute at the University of Utah; University of Michigan Comprehensive Cancer Center; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; UC San Diego Moores Cancer Center; Fred & Pamela Buffett Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; The University of Tennessee Health Science Center; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute; University of Colorado Cancer Center; Aim at Melanoma; Vanderbilt-Ingram Cancer Center; Mayo Clinic Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Yale Cancer Center/Smilow Cancer Hospital; Fox Chase Cancer Center; Dana-Farber/Brigham and Women's Cancer Center; The University of Texas MD Anderson Cancer Center; Duke Cancer Institute; Roswell Park Cancer Institute; Stanford Cancer Institute; Massachusetts General Hospital Cancer Center; Moffitt Cancer Center; City of Hope Comprehensive Cancer Center; University of Alabama at Birmingham Comprehensive Cancer Center; and National Comprehensive Cancer Network.

PMID: 27496110
DOI: 10.6004/jnccn.2016.0101

Abstract

The NCCN Guidelines for Melanoma have been significantly revised over the past few years in response to emerging data on a number of novel agents and treatment regimens. These NCCN Guidelines Insights summarize the data and rationale supporting extensive changes to the recommendations for systemic therapy in patients with metastatic or unresectable melanoma.

Publication types

Practice Guideline

MeSH terms

Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Combined Modality Therapy
Humans
Immunotherapy
Melanoma / diagnosis*
Melanoma / etiology
Melanoma / therapy*
Molecular Targeted Therapy
Neoplasm Staging
Retreatment
Treatment Outcome

Substances

Antineoplastic Agents